Photo of Robert Z. Orlowski from faculty.mdanderson.org
May 10, 2024, 01:01
Myeloma Paper of the Day, May 9th, suggested by Robert Orlowski
Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: University Hospital of Salamanca’s experience with T-cell redirecting therapies in triple-class refractory myeloma suggests OS is better with CAR T approaches vs. bispecifics and CAR T failure best salvaged with bispecific antibodies.”
Authors: Borja Puertas, Adolfo Fernández-Sánchez, Elena Alejo, Beatriz Rey-Bua, Ana África Martín-López, Estefaía Pérez López, Miriam Lopez-Parra, Lucia Lopez-Corral, Norma Gutierrez, Ramón García-Sanz, Noemi Puig, Veronica Gonzalez-Calle, and Maria-Victoria Mateos.
Source: Robert Orlowski/X
Other insights by Robert Orlowski on OncoDaily.
Adolfo Fernández-Sánchez
Ana África Martín-López
Beatriz Rey-Bua
Bispecific antibodies
Borja Puertas
cancer
Elena Alejo
Estefaía Pérez López
Lucia Lopez-Corral
Maria-Victoria Mateos
MD Anderson Cancer Center
Miriam Lopez-Parra
multiple myeloma
Myeloma
Myeloma Paper of the Day
Noemi Puig
Norma Gutierrez
OncoDaily
Oncology
Ramón García-Sanz
Robert Orlowski
University Hospital of Salamanca
Veronica Gonzalez-Calle
AMP